Shots:
The companies collaborated to develop “off-the-shelf” CAR-iMAC cell therapy for cancer immunotherapy
The collaboration will combine both companies’ technologies and expertise along with the R&D capabilities, manufacturing, and marketing to develop CAR-iMAC clinical products for the treatment of solid tumors
CellOrigin Biotech focuses to develop innovative technologies in cell therapy and builds a valuable products pipeline & also plans to work with other collaborators to explore and develop innovative anti-tumor drugs to address the unmet needs of cancer patients. Qilu has launched 200+ products with 30+ products “first to launch” in China and 3 products “D181 launch” in the US
Ref: PRNewswire | Image: CellOrigin Biotech
